NEW YORK (GenomeWeb News) – Asuragen and Life Technologies have entered into an exclusive agreement to develop and commercialize a molecular diagnostic test to aid physicians in monitoring and treating patients with chronic myeloid leukemia.

Asuragen's BCR/ABL1 assay will simultaneously detect and quantify BCR/ABL1 fusion transcripts (b2a2, b3a2, and e1a2) in a single reaction, Austin, Texas-based Asuragen said. The BCR/ABL1 fusion transcripts are present in roughly 95 percent of CML and 25 percent to 30 percent of patients with acute lymphoblastic leukemia, the firm added.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.